<div>
  <ul>
    <li>
      <p>
        Genetic testing company Variantyx has launched IriSight CNV Analysis, a genome-based test devised to detect chromosomal abnormalities related to clinical symptoms in fetuses or pregnancies that might lead to genetic disorders or pregnancy loss.
      </p>
    </li>
    <li>
      <p>
        IriSight CNV Analysis reportedly facilitates the sequencing of the entire genome, which enables the detection of a range of chromosomal abnormalities including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity, and possible uniparental disomy. In addition, the test is claimed to provide reflex options for cases with non-diagnostic outcomes.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20231110772254/en/Variantyx-Expands-Its-Reproductive-Health-Offerings-with-Launch-of-a-Direct-Replacement-for-Chromosomal-Microarray-Analysis">
      <b>Press release</b>
    </a>
  </p>
</div>


Precision Medicine

DISRUPTOR_PRESENT

PROMINENT_CATEGORY

<div>
 <ul>
  <li><p>Genetic testing company Variantyx has released IriSight CNV Analysis, a genome-based test that detects chromosomal abnormalities in fetuses or pregnancies that may lead to genetic disorders or pregnancy loss.</p></li>
  <li><p>IriSight CNV Analysis can sequence the entire genome and identify a range of chromosomal abnormalities including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity, and possible uniparental disomy. The test also offers reflex options for cases with non-diagnostic outcomes.</p></li>
 </ul>
</div>

Variantyx launches IriSight CNV Analysis for chromosomal abnormality detection

<div>
 <ul>
  <li><p>Genetic testing company Variantyx secured additional funding from its portfolio of investors, which includes Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners, 20/20 HealthCare Partners, and Peregrine Ventures.</p></li>
  <li><p>The funds raised are expected to be used for commercial expansion.</p></li>
  <li><p>With this, the total amount invested in Variantyx amounts to over USD 120 million.</p></li>
 </ul>
</div>

All Updates

Variantyx launches IriSight CNV Analysis for chromosomal abnormality detection

Variantyx secures additional funding from portfolio of investors